AB0433 The association of serum adiponectin levels with insulin resistance and inflammatory parameters in patients with rheumatoid arthritis. (23rd January 2014)

• Record Type: Journal Article
• Authors: Yasar Bilge, S.; Kasifoglu, N.; Kasifoglu, T.; Gonullu, E.; Korkmaz, C.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 662
• Page End: 662
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.433
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Rheumatoid Arthritis (RA) is a chronic, inflammatory, autoimmune disease (1). Adiponectin is an adipocytokin which has anti-atherogenic, anti-angiogenic, anti-inflammatory and anti-tumor effects (2). Adiponectin also increases the sensitivity to insulin (3). Objectives: The aim of this study was to investigate the relationship between disease activity, acute phase response, insulin resistance and adiponectin levels, known to have antiinflammatory effects in RA. Methods: Sixty-five patients with RA and thirty patients with osteoarthritis (OA) who fulfilled the American College of Rheumatology (ACR) classification criteria for each disease were included for this study. Patients who have a previous history of diabetes mellitus or recieving oral anti-diabetic agents, insulin, anti-obesity drugs or disease modifying anti-rheumatismal drugs were excluded. Body mass index, acute phase reactants, DAS-28, fasting blood glucose, insulin levels and adiponectin levels were measured at the beginning (0. month) and 3th month of the therapy in RA patients. Results: Adiponectin levels at the third month of the therapy were significantly increased compared with baseline levels. However there was no correlation between adiponectin levels and disease activity or acute phase reactans in both baseline and third month of the therapy. Acute phase response and DAS-28 decreased at the end of the 3rd month, as expected. The decrease in insulin resistance was statistically non-significant.There was no correlation between adiponectin levels and insulin resistance at the begining of the therapy but there was an inverse correlation at the end of 3rd month. Conclusions: We believe that the cause of elevation in adiponectin levels and the decrease in insulin resistance are the results of immunsupresive therapy used in treatment of RA. References: Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108 Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003; 148:293-300 Kadowaki T, Yamauchi T. Adiponectin ve adiponectin receptors. Endocrine Reviews 2005; 26(3): 439-451 Disclosure of Interest: None Declared